OpenURL Connection Search

Select item for more details and to access through your institution.

hADA3 is required for p53 activity.
Published in:
EMBO Journal, 2001, v. 20, n. 22, p. 6404, doi. 10.1093/emboj/20.22.6404
By:
- Wang, Ting;
- Kobayashi, Takahiko;
- Takimoto, Rishu;
- Denes, Alec E.;
- Snyder, Eric L.;
- el-Deiry, Wafik S.;
- Brachmann, Rainer K.
Publication type:
Article
Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations.
Published in:
EMBO Journal, 1998, v. 17, n. 7, p. 1847, doi. 10.1093/emboj/17.7.1847
By:
- Brachmann, Rainer K.;
- Kexin Yu;
- Eby, Yolanda;
- Pavletich, Nikola P.;
- Boeke, Jef D.
Publication type:
Article
Phase Ib clinical trial of the anti-frizzled antibody vantictumab (OMP-18R5) plus paclitaxel in patients with locally advanced or metastatic HER2-negative breast cancer.
Published in:
Breast Cancer Research & Treatment, 2020, v. 184, n. 1, p. 53, doi. 10.1007/s10549-020-05817-w
By:
- Diamond, Jennifer R.;
- Becerra, Carlos;
- Richards, Donald;
- Mita, Alain;
- Osborne, Cynthia;
- O'Shaughnessy, Joyce;
- Zhang, Chun;
- Henner, Randall;
- Kapoun, Ann M.;
- Xu, Lu;
- Stagg, Bob;
- Uttamsingh, Shailaja;
- Brachmann, Rainer K.;
- Farooki, Azeez;
- Mita, Monica
Publication type:
Article
Genome wide screens in yeast to identify potential binding sites and target genes of DNA-binding proteins.
Published in:
Nucleic Acids Research, 2008, v. 36, n. 1, p. e8, doi. 10.1093/nar/gkm1117
By:
- Zeng, Jue;
- Yan, Jizhou;
- Wang, Ting;
- Mosbrook-Davis, Deborah;
- Dolan, Kyle T.;
- Christensen, Ryan;
- Stormo, Gary D.;
- Haussler, David;
- Lathrop, Richard H.;
- Brachmann, Rainer K.;
- Burgess, Shawn M.
Publication type:
Article
Groups of p53 target genes involved in specific p53 downstream effects cluster into different classes of DNA binding sites.
Published in:
Oncogene, 2002, v. 21, n. 51, p. 7901, doi. 10.1038/sj.onc.1205974
By:
- Hua Qian;
- Ting Wang;
- Naumovski, Louie;
- Lopez, Charles D.;
- Brachmann, Rainer K.
Publication type:
Article
Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss of heterozygosity as an important aspect of p53 status in human cancers.
Published in:
Carcinogenesis, 2007, v. 28, n. 2, p. 289, doi. 10.1093/carcin/bgl132
By:
- Lawrence R. Dearth;
- Hua Qian;
- Ting Wang;
- Timothy E. Baroni;
- Jue Zeng;
- Stephanie W. Chen;
- Sun Young Yi;
- Rainer K. Brachmann
Publication type:
Article
p53 transactivation is involved in the antiproliferative activity of the putative tumor suppressor RBM5.
Published in:
International Journal of Cancer, 2011, v. 128, n. 2, p. 304, doi. 10.1002/ijc.25345
By:
- Kobayashi, Takahiko;
- Ishida, Junich;
- Musashi, Manabu;
- Ota, Shuichi;
- Yoshida, Takeshi;
- Shimizu, Yuichi;
- Chuma, Makoto;
- Kawakami, Hiroshi;
- Asaka, Masahiro;
- Tanaka, Junji;
- Imamura, Masahiro;
- Kobayashi, Masanobu;
- Itoh, Hiroshi;
- Edamatsu, Hironori;
- Sutherland, Leslie C.;
- Brachmann, Rainer K.
Publication type:
Article
Choosing where to look next in a mutation sequence space: Active Learning of informative p53 cancer rescue mutants.
Published in:
Bioinformatics, 2007, v. 23, n. 13, p. i104, doi. 10.1093/bioinformatics/btm166
By:
- Samuel A. Danziger;
- Jue Zeng;
- Ying Wang;
- Rainer K. Brachmann;
- Richard H. Lathrop
Publication type:
Article

Found: 8